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aim: To explore the relationship between pathophysiological factors and premature lung 
aging in a cohort of community-dwelling subjects in a health-screening setting.
Methods: 16,107 pharmacy customers in Germany (5954 males, 10,153 females; 
mean age 59.7  years) participated in a lung function screening project by providing 
demographic data, including smoking status and known airway conditions and per-
forming spirometry with a Vitalograph, a spirometry screening device. Lung age was 
calculated from the spirometric findings, and the difference between chronological age 
and calculated lung age was analyzed in its relationship to the demographic data in 
general linear models.
results: In the overall cohort, calculated lung age exceeded chronological age by 
10.0 years. Based on the subset of non-smokers not reporting any airway conditions, 
Vitalograph data in this setting may underestimate FEV1 to some degree, but this appar-
ently had little impact on the detection of association of lung age with pathophysiological 
factors or the corresponding effect sizes. The most important factors associated with 
greater lung age based on strength of association were presence of dyspnea, being 
a smoker, and reporting a history of COPD or asthma. Corresponding effect sizes for 
the difference between age and lung age were 6.5, 5.7, 13.9, and 8.3 years over the 
chronological age.
Discussion and conclusion: These data confirm the usefulness of screening devices 
of lung function testing for epidemiological but potentially also for pharmaco-epidemio-
logical studies.
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inTrODUcTiOn
We all age, and that is not bad at all because there would be no 
life without aging. Lung function physiologically declines with 
aging, but only accelerated aging of the lung, due to inhalation 
of noxious substances, such as smoking, is bothersome and can 
lead to morbidity and incapability. Aging is inevitable, but healthy 
aging with maintenance of a good function can be expected. This 
requires understanding of the aging process and removal of fac-
tors associated with and perhaps even causing unhealthy aging, 
i.e., premature or accelerated functional decline.
Similar to other organs, the lung also exhibits age-associated 
changes (1). These include a reduced lung volume, ciliary dys-
function, and alterations of the respiratory muscles, leading to 
a reduced pulmonary efficacy and cough strength. Underlying 
physiological processes also include complex changes in immunity 
(1), increased extracellular matrix deposition (2), and an altered 
responsiveness of the receptor systems regulating lung function 
(3, 4). Moreover, the senescent lung is also more susceptible to 
injury as documented in many animal models (5), potentially 
creating a vicious cycle of age-associated functional impairment 
and even greater additional damage upon injury.
Clinical studies of age-related changes in pulmonary function 
are often based on key spirometric parameters, such as forced 
expiratory volume in 1 s (FEV1) and forced vital capacity (FVC); 
forced expiratory volume in 6 s (FEV6) is a suitable alternative 
to FVC in studies of lung function (6, 7). Therefore, other than 
symptom assessment (8), changes in FVC, FEV1, and FEV6 have 
often been used to study the physiological decline of lung func-
tion with advancing age and how this is affected by pathological 
conditions.
The physiological relationship between age, height, gender, 
and ethnicity, on the one hand, and lung function, on the other 
hand, was described in healthy subjects in several sets of refer-
ence equations, e.g., European Community for Steel and Coal 
(ECSC) (9), National Health and Nutrition Examination Survey 
(NHANES) III (10), and most recently and most comprehen-
sively, the Global Lung Initiative (GLI) 2012 (11). GLI reference 
equations are available both for children and adults up to 95 years 
old, for four different ethnicities. Of note, GLI reference equa-
tions describe a greater respiratory capacity for a given age than 
ECSC equations.
The decline in lung function with aging is greater than 
expected in some patients, which has led to the concept of “lung 
age.” Usually, the observed FEV1 will be related to that for gender, 
ethnicity, chronological age, and height-matched predicted value 
(“% predicted”). By contrast, lung age relates the observed FEV1 
to the age for which the measured value equals 100% predicted. A 
low observed FEV1 of a 48-year-old man (e.g., 2.85 L, correspond-
ing to only 75% of age matching predicted mean) will be now 
matched to a corresponding higher age (e.g., 2.85 L equals 100% 
for a 71-year-old man). It is assumed that premature lung aging 
has occurred due to pathophysiological factors. For instance, 
increased lung age is observed in patients with COPD (12). Other 
than providing potentially interesting information on pulmonary 
pathology, it has been proposed that determination of lung 
age may be an educational tool, e.g., help to motivate smoking 
cessation (13, 14). The concept of organ age as an indicator of 
organ-specific premature aging has also been established for the 
heart, where it also has been suggested as an educational tool to 
motivate healthier life styles (15).
The Vitalograph copd-6 spirometer is a portable electronic 
device primarily developed for screening purposes, particularly 
with regard to COPD (16). It measures FEV1 and FEV6 based 
on forced expiration and, with additional input of gender and 
height, calculates lung age based on the gender-specific ECSC 
equations (9). The positive and negative predictive values of 
detecting airway obstruction with the Vitalograph have been 
documented (17). The protocol of a validation study compar-
ing Vitalograph data to those of conventional spirometry 
(18) and reports of a small-scale screening project have been 
published (19).
Against this background, the present study was designed 
to screen a large number of community-dwelling pharmacy 
customers and determine their lung age. We then related the 
difference between lung age and chronological age to various 
known pathophysiological factors to explore the usefulness of 
the Vitalograph, for instance, for future use as an easily under-
standable and popular smoking cessation aid and/or support of 
pharmaco-epidemiological studies.
MaTerials anD MeThODs
Ethical committee approval was neither required nor recom-
mended for this type of study in Germany at the time it was per-
formed. Similarly, the lung function testing offered to the general 
public during the 2014 congress of the European Respiratory 
Society held in Munich, Germany1 also did not involve ethical 
committee approval.
Between November 1 2013 and January 31 2014, 704 German 
pharmacies were invited to participate in the study. Each phar-
macy was supplied with case record forms and a Vitalograph 
copd-6 spirometer (Vitalograph GmbH, Hamburg, Germany) 
and received basic training in its use. During the study period, 
each pharmacy was requested to offer each customer participa-
tion in the study. Study participation was voluntary and anony-
mous and included both a lung function test on the Vitalograph 
and completing a case record form. This included subject gender, 
chronological age, height, population size of home town (< vs. 
>100,000 inhabitants), presence of cough (no, yes; if yes, acute or 
chronic and with or without expectoration), presence of dyspnea 
(no, yes; if yes, during usual daily activities or paroxysmal), 
smoking habit (no, yes; if yes, duration of up to or more than 
10 years and frequency of incidentally, 1–10, 11–20, 21–30, and 
>30 cigarettes per day), presence of allergies (no, yes), and pres-
ence of current airway conditions (none, common cold, COPD, 
asthma, and “other”). For information of the pharmacy and the 
participant, the case record form provided operational definitions 
related to cough and dyspnea (Table 1).
FEV1, FEV6, and calculated lung age as determined by the 
Vitalograph measurement were to be entered into the case record 
1 http://erscongress.org/programme/patient-organisation-programme.html
1 9 ,1 9 7 p a r t ic ip a n ts
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- te c h n ic a lly in v a lid m e a s u rem e n t (3 9 5 )
- m is s in g g e n d e r d a ta (2 6 )
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FigUre 1 | Disposition of participants. For some subjects, more than 
one exclusion criterion applied; for details, see Section “Materials and 
Methods.”
TaBle 1 | Operational definitions related to cough and dyspnea provided 
to pharmacy and study participants on the case record forms.
– “Chronic” cough: “recurrent (multiple times per month) or regularly or 
continuously (almost daily for at least 8 weeks)”
– “Dyspnea”: “difficulty of deep inhalation, heavy breathing or rapid exhalation”
 o  “Paroxysmal”: “only in specific situations [e.g., stress, sport, allergens  
(pollen, house dust, animal hair)]” 
 o “Usual daily activity”: “e.g., when climbing stairs”
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form. The Vitalograph calculates lung age for men and women 
based on equations provided by Morris and Temple (13), which 
after conversion to metric units are
 
Lung age 113 height 31 25 observed FEV
39 375 males
1= ( ) ( )
(
• − •
−
.
.
0
)  
 
Lung age 14 height 4 observed FEV
77 28  female
1= ( ) ( )0 0 000
0
• − •
−
.
. s( ).  
The manufacturer reports the accuracy of the Vitalograph to 
be <±3%.
In most cases, FEV1 and FEV6 were entered into the case record 
forms as absolute value; however, in some cases, FEV1 was given 
as percentage of predicted value (FEV1_%-predicted), a variable 
also provided by the Vitalograph. These percentage values were 
converted into absolute values based on the following equations, 
which are used by the Vitalograph to calculate the percentage 
values:
 
FEV 3 62 height 32 chronological age 1 26
FEV pr
1
1
= −( )
−
. . .
_%
• − •
•
0 0 0
edicted males( )  
 
FEV 3 5 height 25 chronological age 1 93
FEV pr
1
1
= − −( )
−
. . .
_%
0 0 0 0• •
• edicted females( )  
In these equations, FEV1 is expressed in liters, height in meters, 
and chronological age in years.
All analyses described here were specified after comple-
tion of the study, but before the case record forms were 
entered into the database and before start of any analysis. 
In total, 19,197 subjects aged 20 years or older participated 
in the study. Subjects were excluded from the analysis if at 
least one of the following predefined criteria applied to them 
(Figure 1):
 – Vitalograph reading of “!,” indicating a technically invalid 
measurement (n = 395).
 – Data missing for gender (n = 26).
 – Data missing for height (n = 137).
 – Data missing for lung age and FEV1 in case record form 
(n = 869).
 – Reported FEV1  >  reported FEV6 in case record form 
(n = 1642).
 – Reported FEV1 value implausible according to gender-specific 
5σ-rule (n = 8).
 – Subjects from four pharmacies with implausible values, iden-
tified by funnel plot (n = 102).
Some subjects were excluded due to more than one criterion.
For the remaining subjects (n = 16,107), the following adjust-
ments were made in the database prior to any analysis:
 – If no response was given for presence of cough (n = 124), smok-
ing (n = 115), allergy (n = 418), common cold (n = 13,921), 
COPD (n = 15,724), asthma (n = 15,227), dyspnea (n = 471), 
or other airway disease (n = 15,378), this was considered as 
absence of the condition. For some subjects, this applied to 
more than one of these variables.
 – In a small number of cases, “no” was indicated for presence of 
cough but positive statements on duration or expectoration 
were provided (n = 5), or “no” was indicated for smoking but 
information on number of cigarettes or duration of smoking 
status was given (n = 5), or “no” was indicated for dyspnea but 
information on frequency of dyspnea was given (n = 7); in 
those cases, the “no” was reset to “yes” for plausibility reasons.
All analyses were performed using 16,107 subjects. In line with 
the post hoc character of the analyses, all statistical analyses are 
descriptive and exploratory. Two-sided P-values below 0.01 were 
interpreted as indicating a significant effect. Data analysis was 
performed using SAS (version 9.4, SAS Institute Inc., Cary, NC, 
USA).
resUlTs
Description of study Population
After application of the predefined exclusion criteria, data from 
16,107 subjects (37.0% men; 28.9% living in large city) were avail-
able for analysis. Their demographic and airway-specific data are 
summarized in Table 2. Participants had a mean chronological 
age of 59.7 years but covered a wide range (20–98 years). 21.2% of 
participants self-identified as smokers, and 16.5% reported being 
a smoker for more than 10 years, mostly reporting not more than 
20 cigarettes per day. Men as compared to women were slightly 
TaBle 3 | association of potential explanatory variables with a greater 
difference between lung age and chronological age.
Vitalograph standard 
equation
equation based on present 
data
P-value change 
in lung 
age ± se
P-value change 
in lung 
age ± se
Dyspnea <0.0001 6.5 ± 0.32 <0.0001 5.8 ± 0.47
Smoker <0.0001 5.7 ± 0.37 <0.0001 6.3 ± 0.53
COPD <0.0001 13.9 ± 0.94 <0.0001 14.1 ± 1.30
Asthma <0.0001 8.3 ± 0.64 <0.0001 8.8 ± 0.91
Chronological 
age decile
<0.0001 See Figure 2 <0.0001 See Figure 2
Height decile <0.0001 See Figure 2 <0.0001 See Figure 2
Cough <0.0001 1.7 ± 0.34 <0.0001 2.0 ± 0.49
Other airway 
disease
<0.0001 3.2 ± 0.69 0.0021 3.1 ± 1.00
Common 
cold
0.0006 1.5 ± 0.45 0.0048 1.8 ± 0.65
Patient-
reported 
allergies
0.0052 −0.9 ± 0.33 0.21 −0.7 ± 0.46
Analyses were performed based on the equations used by the Vitalograph (“Vitalograph 
standard equation”) and the equation we have empirically derived in the subset of non-
smokers not reporting any airway disease in this study (“equation based on present data”). 
Results are based on a selection procedure to identify predictors of high lung age using a 
multivariate linear model and shown as parameter estimates with SE and corresponding 
p-value. Parameter estimates are displayed in the sequence of inclusion into the model 
(based on F-tests). For categorical variables effects are relative to the respective control 
group of non-smoker, and absence of cough, allergies, COPD, asthma, dyspnea, or other 
airway disease. Note that the parameter estimates for chronological age and height are 
given for gender-specific deciles, respectively. Size of home town is not included because 
it did not reach the predefined threshold level of p < 0.15 for staying in the model. The 
parameter estimate for change in lung age is expressed in years.
TaBle 2 | Demographic and airway-specific data in the total study group 
and in subgroups of male and female participants.
Total Males Females
Demographics
Number 16,107 5954 10,153
Age, years 59.7 ± 16.4 61.3 ± 16.5 58.7 ± 16.2
Height, centimeter 168.9 ± 9.1 176.6 ± 7.3 164.4 ± 6.7
Living in large town, % 28.9 29.7 28.4
Smoker, % 21.2 23.3 20.0
Smoker for more than 
10 years, %
16.5 18.4 15.4
Smoker with 1–10/ 
11–20/21–30/>30 
cigarettes/day, %
7.6/8.3/3.0/0.8 6,9/9.5/3.9/1.5 8.0/7.6/2.4/0.4
Patient symptoms and disease history
Cough, % 33.8 32.6 34.4
Cough with 
expectorations, %
18.3 19.2 17.7
Chronic cough, % 17.5 16.0 18.3
Dyspnea, % 31.6 24.6 35.6
During usual daily 
activities, % 
16.3 11.8 18.9
Patient-reported allergies, 
% 
26.0 18.9 30.1
Common cold, % 13.6 13.4 13.7
COPD, % 2.4 2.8 2.1
Asthma, % 5.5 4.0 6.3
Other airway disease, % 4.5 4.0 4.8
airway parameters
FEV1, L 2.33 ± 0.86 2.78 ± 0.94 2.07 ± 0.69
FEV1, % predicted 87.5 ± 22.6 87.5 ± 24.4 87.6 ± 21.5
FEV6, L 
(n = 11,574/4274/7300)
2.91 ± 1.01 3.50 ± 1.10 2.57 ± 0.78
Lung age, years 69.8 ± 24.3 71.0 ± 25.0 69.0 ± 23.8
Difference lung 
age – chronological age, 
years
10.0 ± 18.9 9.5 ± 19.8 10.2 ± 18.3
Data are means ± SD or percentage of respective group.
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older, more likely to be a smoker and, if a smoker, tended to 
smoke more cigarettes per day (Table 2).
Cough was reported in 33.8% of the study population, and 
more than half of those reported chronic cough and/or cough 
with expectorations (Table  2). Dyspnea, allergies, common 
cold, COPD, asthma, and other airway diseases were reported in 
31.6, 26.0, 13.6, 2.4, 5.5, and 4.5%, respectively. As compared to 
women, men reported cough less frequently but more frequently 
cough with expectorations. Notably, men reported dyspnea and 
allergies much less frequently than women (Table 2).
The mean measured FEV1 and FEV6 was 2.33 and 2.91  L, 
respectively, with men, as expected, exhibiting larger values than 
women (Table 2). Calculated lung age was 69.8 years in the total 
population, which was 10.0  years greater than chronological 
age; this difference was smaller in men than in women (9.5 vs. 
10.2 years, Table 2).
Method Validation
Considering that Vitalograph measurements in a screening set-
ting with limited training of pharmacy personnel may lead to 
falsely low estimates of FEV1 due to submaximal effort in forced 
expiration, we have used the group of non-smokers not reporting 
any type of airway disease with documented FEV1 values (1521 
males, 2006 females) to determine the linear relationship of FEV1 
to height and chronological age in our dataset. This was done by 
the Global Linear Model procedure in SAS. The resulting coef-
ficients in the equations are similar to those reported by Morris 
and Temple (13). They were as follows (with 95% CI for estimates 
of coefficients):
 
FEV 3 25 height 3 2 chronological age 973 males1
2 7
= ( ). . .
( .
• − • −0 0 0 0
6 3 75 277 333 31 1 91− − − −. ) ( . . ) ( . . )0 0 0 0 0 0  
 
FEV 2 99 height chronological age females1
2
= ( ). . .
( .
• − • −0 0243 1 31
66 3 33 230 257 1 89− − −. ) ( . . ) ( . . )0 0 0 0 0 732  
analyses Using Multiple linear Models
Taking into account the large inter-individual variation of the dif-
ference between lung age and chronological age, we have applied 
general linear model methodology to explore factors associated 
with an older lung age. The model selection procedure included 
gender, chronological age, height, city size, smoking status, and 
presence of cough, common cold, allergies, dyspnea, COPD, 
asthma, and “other respiratory disease” as potential explana-
tory variables (Table 3). The stepwise selection process applied 
TaBle 4 | association of additional explanatory variables with a greater 
lung age in the subsets of subjects with dyspnea, smokers, and subjects 
with cough and respective additional information.
change in  
lung age ± se
p-value
subset of subjects with dyspnea (n = 4773)
Dyspnea during usual daily activities vs. 
paroxysmal dyspnea
5.0 ± 0.56 <0.0001
subset of smokers (n = 3190)
1–10 cigarettes/day 6.1 ± 1.92 0.0016
11–20 cigarettes/day 9.2 ± 1.92 <0.0001
21–30 cigarettes/day 12.2 ± 2.07 <0.0001
>30 cigarettes/day vs. occasional smoking 15.4 ± 2.61 <0.0001
Duration of smoking >10 years vs. ≤10 years −1.2 ± 1.03 0.25
subset of subjects with cough (n = 4895)
Expectoration vs. no expectoration 1.0 ± 0.56 0.072
Chronic vs. acute −0.7 ± 0.60 0.22
These analyses were performed based on the equations built into the Vitalograph.  
The parameter estimate for change in lung age is expressed in years.
FigUre 2 | gender-specific associations between gender and chronological age (upper panels) and height (lower panels) for the difference between 
lung age and chronological age. Numbers in the left panels are based on the ECSC equations build into the Vitalograph, numbers in the right panels based on 
the empirically derived equations in non-smokers not reporting any airway condition. The scale of the x-axis represents deciles of male or female subjects for age 
and height. Each decile includes the data from 10% of subjects in ascending order of age or height, respectively, see Table 3. Note that the depiction based on our 
empirical equations may in part reflect a self-fulfilling prophecy as some of the data went into the derivation of the equation and the depicted data.
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parameter-specific P-limits of 0.25 for entry into the model and 
of 0.15 for stay in the model. As we empirically found a differ-
ent equation to better describe chronological age-, height-, and 
gender-specific FEV1 in non-smokers not reporting any airway 
disease (see previous paragraph), the models were applied using 
the equations used by the Vitalograph and those empirically 
determined by us. Both models yielded very similar information 
regarding the factors identified as being possibly associated with 
the difference between chronological age and lung age. The strong-
est association (based on F-statistic) existed for dyspnea with a 
parameter estimate of 6.5 and 5.8 in the two models; this means, 
that with all other factors being equal subjects with dyspnea had 
an additional 6.5 or 5.8 years greater difference between lung age 
and chronological age if compared to subjects without dyspnea. 
Other parameters associated with an older lung age in descending 
order of strength of association were: being a smoker, presence of 
COPD, presence of asthma, chronological age and height decile, 
presence of cough, presence of “other airway disease,” and pres-
ence of common cold; presence of allergies did not consistently 
exhibit a significant association across the two models, possibly 
because it was a weak relationship even in the model that detected 
it as significant. Of note, the association between lung age and 
chronological age or height may not be strictly linear (Figure 2).
To further explore the impact of additional information on 
dyspnea, smoking, and cough, the same linear models were 
applied to the subsets of participants with the respective char-
acteristic (Table 4) and available additional information. In the 
subset of subjects with dyspnea (n = 4773), subjects reporting it 
during usual daily activities by average had a 5.0 years older lung 
age than those with paroxysmal dyspnea. While smokers had a 
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greater lung age than non-smokers (Table 3), a dose–response 
relationship for number of cigarettes smoked per day and dif-
ference between lung age and chronological age was observed 
among the 3190 smokers; parameter estimates for the difference 
between lung age and chronological age increased from 6.1 in 
those consuming up to 10 cigarettes per day to 15.4 in those 
smoking more than 30 cigarettes per day as compared to those 
reporting occasional smoking only (Table  4). However, dura-
tion of smoking habit for >10 vs. ≤10  years did not exhibit a 
significant contribution. Finally, in the subset of participants with 
cough (n = 4895) neither presence of expectoration nor chronic 
vs. acute cough had significant contributions.
DiscUssiOn
The present study demonstrates a difference of 10 years between 
lung age and chronological age in a large cohort of community-
dwelling subjects. This is even more remarkable as the calculation 
of lung age by the Vitalograph is based on the ECSC equations 
(9), which, relative to the GLI 2012 equations (11), underesti-
mate predicted FEV1. Accordingly, the difference between lung 
age and chronological age may be even larger than found here.
limitation of Methods
The current study is based on community-dwelling subjects visit-
ing a pharmacy for any reason. While the participating pharma-
cies were requested to offer study participation to each customer, 
it is possible that subjects concerned about their lung function 
may have been more likely to participate than those without. 
Thus, the pharmacy setting implies that our cohort despite being 
population based may be biased toward people having health 
complaints. This possible selection bias needs to be taken into 
consideration in the interpretation of both the demographic and 
the lung function data. However, we consider this unlikely to have 
limited our regression analysis to determine factors associated 
with lung age as it affects the distribution between healthy and 
diseased participants as compared to a population-based cohort 
but should have limited effect on the association between patho-
physiology and lung age.
Lung function is known to differ to some extent between 
ethnic groups with highest values for Caucasians (11). Our 
case record forms did not capture ethnicity of the participants 
because non-Caucasians account for only a very small part of 
the German population. We also did not capture other known 
risk factors for poor lung function, such as preterm delivery/low 
birth weight or cardiovascular disease, specifically congestive 
heart failure. Based on the screening character in a pharmacy 
setting involving community-dwelling participants, we could 
only document a limited amount of parameters on each subject 
for pragmatic reasons, as is typical for such large-scale screening 
projects (20). For the same reason, our questionnaire had cap-
tured present number of daily cigarettes and presence of smok-
ing status for less vs. more than 10  years. The dose–response 
relationship between smoking and COPD has largely been 
established for pack-years of cigarettes, but this parameter may 
be too complex to determine in a screening setting. Moreover, 
screening methods are optimized to be sensitive and not to have 
specificity; thus, low FEV1/high lung age does not establish a 
diagnosis but should rather be seen as stimulus to seek further 
clarification by a physician.
The validity of spirometry depends on several factors, includ-
ing correct assessment of height, use of the device, maximum 
expiratory effort (effort dependence), and time between inspira-
tion and forced expiration (time dependence). While participat-
ing pharmacy staff had received some training in the correct use 
of the Vitalograph, it is possible that the overall technical quality 
of the measurements may have been lower than, for instance, 
measurements in a physician office (16). We consider this, 
particularly a suboptimal expiratory effort, to be the most likely 
reason why our empirical data in non-smokers without reported 
airway disease for any given chronological age exhibited smaller 
FEV1 as compared to the ECSC reference equation (9). While this 
may have affected the absolute difference between chronological 
age and lung age, based on the data in Table 3, it apparently had 
only little impact on the assessment of factors associated with 
premature lung aging. Moreover, it should be considered that 
the classic expression of lung function as percentage predicted of 
FEV1 has lower limits of being accepted as “normal”.2 By contrast, 
the concept of lung age is not meant to be normative but rather 
provides a range of possible values that may or may not be con-
sidered as pathological.
A final technical consideration relates to the fact that physi-
cians are primarily interested in effect sizes of associations. 
While we report such effect sizes, our regression models ranked 
parameters primarily by strength of association. Effect size and 
strength of association may not be tightly related, as a parameter 
with great variability in the population may exhibit a large effect 
size but nevertheless a rather weak association. This may explain 
why in our analysis, dyspnea had a considerable effect size but 
only a weaker association as compared to other parameters, as 
dyspnea is known to be a multifactorial symptom that exhibits 
great variability in the population. However, irrespective of the 
underlying cause of dyspnea, be it pulmonary, cardiac, or other, 
its presence has a negative impact on spirometry.
Factors associated with high lung age
The concept of lung age and its assessment by the Vitalograph 
have previously mainly been used in the screening for COPD (16, 
17) and to motivate cessation of smoking (13, 14). However, it has 
been used in small populations only to provide pathophysiologi-
cal information (19). Our study relates information on lung aging 
to possible pathophysiologically relevant factors for a cohort of 
more than 16,000 subjects. The respective role of such factors 
detected in our study is in line with general knowledge on the 
pathophysiology of lung disease.
Dyspnea is a symptom that can be due to a range of pulmo-
nary, cardiac, and other conditions. It was reported by almost a 
third of our study participants, of which about half reported it to 
occur during usual daily activities, such as climbing stairs. This 
prevalence is similar to that reported in a recent meta-analysis 
2 www.goldcopd.org
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of dyspnea studies in people aged 65 and older (8). While our 
cohort is younger than that reported by van Mourik et al., we 
have recruited solely pharmacy customers, which may have 
introduced a health bias. As in the meta-analysis by van Mourik 
et  al., dyspnea was observed more frequently in women than 
men in our study. The presence of dyspnea was associated 
with a lung age exceeding chronological age by approximately 
6  years; among subjects with dyspnea, lung age was approxi-
mately 5  years greater in those experiencing it during usual 
daily activities than those experiencing it only upon exertion. 
Overall, despite inclusion of 7.9% of patients with self-reported 
COPD and asthma in the model, dyspnea exhibited a stronger 
association with greater lung age than any other explanatory 
variable in our study.
Being a smoker had the second strongest association with 
greater lung age among candidate parameters in our study. The 
adverse effects of smoking on lung function are well known (21) 
(see text footnote 2). Being a smoker was associated with an 
increase in lung age by approximately 6 years in our study. Within 
the group of smokers, a clear dose-dependency of premature 
lung aging was found ranging from 6.1 to 15.4 years for those 
smoking 1–10 and those smoking more than 30 cigarettes per 
day, respectively, if compared to those smoking only occasionally. 
This is consistent with a smaller Vitalograph-based study, which 
reported greater airflow limitation in those smoking more than 
20 as compared to those smoking less than 20 cigarettes per day 
(19). While these findings certainly are not surprising, it was 
proposed that confronting smokers with their greater lung age 
might aid cessation efforts (13, 14). Similarly, it has been proposed 
that calculated heart age may aid educational efforts to promote 
healthier life styles (15).
Self-reported COPD and asthma had somewhat weaker 
associations with lung aging, but with approximately 14 and 
8.5  years had greater estimated effect sizes for the associa-
tion with lung age than any other parameter (see “Limitation 
of Methods”). These effect sizes are not surprising given that 
the hallmarks of physiological lung aging are similar to those 
observed in obstructive airway disease (1, 2), i.e., that obstruc-
tive airway disease adds to the alterations that occur as part of 
normal aging. Thus, our data support the hypothesis that COPD 
can be seen as a condition of accelerated aging of the lung (12). 
By contrast, cough, other airway diseases (not specified as part 
of the study), and common cold exhibited weaker associations 
and only small effect sizes on lung structure and function. This 
is not surprising as common cold and acute cough are too short-
acting to impact lung age. Among those reporting cough, the 
presence of expectorations and of chronic vs. acute cough did 
not affect lung age estimates. Presence of allergies, self-reported 
by a quarter of all study participants, had only very weak and 
inconsistent effects on lung age, possibly reflecting that the 
general public uses a much more lenient definition of allergy 
than the medical community, implying an over-reporting by 
medical standards.
Two parameters exhibiting moderately strong associations 
with greater lung age were chronological age and height. That 
height showed up as significant factor despite being part of the 
equation to calculate lung age may indicate that its association 
with lung age may not be as linear as the equations provided by 
Morris and Temple (13) would suggest. Our exploration by age 
deciles (Figure 2) supports this hypothesis and suggests that this 
may be largely driven by female participants. In fact, introducing 
z-scores in the interpretation of spirometry and abandoning fixed 
ranges (i.e., >80% predicted = normal) also supports this view, 
particularly for older women (11). That chronological age is also 
associated with a greater difference between lung age and chrono-
logical age may reflect that the older lung is more vulnerable to 
lung injury (5), and hence, for any given pathological stimulus, 
incurs greater damage, leading to a higher lung age estimate. In 
this context, one should realize that as lung age in contrast to 
percentage predicted FEV1 does not have lower limits to separate 
physiological from pathological values.
cOnclUsiOn
Based on a systematic analysis of the available evidence, the 
U.S. Preventive Services Task Force has concluded in 2008 that 
a general screening for COPD based on spirometry was ineffec-
tive as it yields many false-positive cases (22). Meanwhile, many 
additional studies using potentially more efficient approaches 
have been reported, including some with handheld spirometric 
devices. Therefore, a recent systematic review and meta-analysis 
has concluded that case finding in targeted groups may be effective 
but stated a need for more research into the optimal identification 
of such targeted groups (23). Such case finding approaches appar-
ently are well accepted by general practitioners (24). Based on a 
large cohort of community-dwelling subjects, our study confirms 
the usefulness and reliability of the Vitalograph by demonstrating 
that it can be used to identify and quantify risk factors associ-
ated with premature lung aging in a large population. Of note, 
detection of such associations is apparently robust and resistant to 
usual screening setting sampling errors with good performance 
of spirometric lung function testing by little-trained providers. 
Possibly, this conclusion is also applicable to other spirometry 
screening devices. Whereas the importance of lung age in smok-
ing cessation is controversial, the method could be used in future 
epidemiological and pharmaco-epidemiological studies.
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